维拉帕米尔编年史:从心血管到胰腺β细胞保护的进展
Hossein Arefanian1, Lubaina Koti2, Sardar Sindhu1,3
1Immunology and Microbiology Department, Dasman Diabetes Institute, Kuwait City, Kuwait.
Frontiers in pharmacology
|December 13, 2023
概括
维拉帕米尔是一种高血压药物,在保护胰腺β细胞和改善糖尿病中C-水平方面具有潜力. 进一步的研究正在探索其应对β细胞损失的机制.
科学领域:
- 心血管药理学心血管药理学
- 内分泌学 在内分泌学.
- 糖尿病研究研究 糖尿病研究
背景情况:
- 维拉帕米尔是一种已知高血压和胸痛的通道阻塞剂.
- 目前的糖尿病治疗方法没有解决β细胞破坏的根本原因.
- 新出现的证据表明,维拉帕米尔可能会保护胰腺β细胞,并维持DM患者的C-水平.
研究的目的:
- 审查维拉帕米尔作为DM潜在治疗剂的历史发展.
- 在DM的背景下提供维拉帕米尔已知的作用机制的最新信息.
- 探索维拉帕米尔对β细胞保护作用的可信机制.
主要方法:
- 对维拉帕米尔的疗效和安全性的文献综述.
- 对临床试验数据的分析表明,维拉帕米尔在DM中具有益处.
- 探索分子通路,包括TXNIP抑制和其他信号通路,由verapamil调节.
主要成果:
- 维拉帕米尔可能会提高并维持C-水平,这表明β细胞功能得到改善.
- 维拉帕米尔降低了与β细胞亡相关的铁素相互作用蛋白 (TXNIP) 表达.
- 该药物经过FDA批准,具有成本效益,并具有已知的安全性.
结论:
- 维拉帕米尔为糖尿病提供了一个有希望的,可访问的治疗选择.
- 了解维拉帕米尔的分子机制对于其在DM中的潜在应用至关重要.
- 对维拉帕米尔对β细胞保护作用的进一步研究可能会导致新的DM疗法.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
459
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
459
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
844
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
844
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
828
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
828
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341


